461 related articles for article (PubMed ID: 9519708)
1. Glucagon-like peptides.
Drucker DJ
Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
[TBL] [Abstract][Full Text] [Related]
2. Minireview: the glucagon-like peptides.
Drucker DJ
Endocrinology; 2001 Feb; 142(2):521-7. PubMed ID: 11159819
[TBL] [Abstract][Full Text] [Related]
3. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
4. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
Baggio LL; Drucker DJ
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
[TBL] [Abstract][Full Text] [Related]
5. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
6. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
7. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
9. The glucagon-like peptides: a double-edged therapeutic sword?
Perry T; Greig NH
Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
[No Abstract] [Full Text] [Related]
10. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 in NIDDM.
Holst JJ
Diabet Med; 1996 Sep; 13(9 Suppl 6):S156-60. PubMed ID: 8894501
[TBL] [Abstract][Full Text] [Related]
12. Central pre-proglucagon derived peptides: opportunities for treatment of obesity.
Larsen PJ; Vrang N; Tang-Christensen M
Curr Pharm Des; 2003; 9(17):1373-82. PubMed ID: 12769729
[TBL] [Abstract][Full Text] [Related]
13. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
Drucker DJ; Lovshin J; Baggio L; Nian M; Adatia F; Boushey RP; Liu Y; Saleh J; Yusta B; Scrocchi L
Ann N Y Acad Sci; 2000; 921():226-32. PubMed ID: 11193827
[TBL] [Abstract][Full Text] [Related]
14. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
15. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
18. Biological actions and therapeutic potential of the glucagon-like peptides.
Drucker DJ
Gastroenterology; 2002 Feb; 122(2):531-44. PubMed ID: 11832466
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.
Nauck MA
Acta Diabetol; 1998 Oct; 35(3):117-29. PubMed ID: 9840447
[TBL] [Abstract][Full Text] [Related]
20. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]